{"id":"W4386282091","doi":"10.1016/s2152-2650(23)00860-1","title":"POSTER: MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Bispecific antibody; Multiple myeloma; Antibody; Oncology; Internal medicine; Immunology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009575534,0.0004311315,0.0006362285,0.0002021855,0.0003402895,0.0005203474,0.000362568,0.000654294,0.005069987],"category_scores_gemma":[0.0005517277,0.0001400575,0.0007998758,0.0001821777,0.0002248979,0.0003426035,0.0002506105,0.001179017,0.0008430475],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006240347,"about_ca_system_score_gemma":0.0005315322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0010416,"about_ca_topic_score_gemma":0.001850372,"domain_scores_codex":[0.999791,0.00007294813,0.00001509594,0.00003449719,0.00002925101,0.00005730954],"domain_scores_gemma":[0.9997196,0.00006092122,0.00003833802,0.00001977728,0.00002517131,0.0001362454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3776109,0.007553339,0.03518073,0.001002213,0.002453571,0.001193509,0.0002960024,0.001473353,0.03745787,0.0004316987,0.05376052,0.4815863],"study_design_scores_gemma":[0.160405,0.1933599,0.4969705,0.0003009715,0.00430758,0.002475536,0.0001850379,0.002086414,0.0242353,0.0009416071,0.1146158,0.0001164533],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.959639,0.01813314,0.0006552908,0.005898208,0.001148868,0.0005350577,0.003878852,0.0001569108,0.009954622],"genre_scores_gemma":[0.977515,0.003745074,0.0008935989,0.003442694,0.000788693,0.0002297233,0.003589025,0.00003940469,0.009756769],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005069987,"threshold_uncertainty_score":0.01696086,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03282828537900095,"score_gpt":0.3300603239609265,"score_spread":0.2972320385819256,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}